Earlier this year, a federal government systems issue prevented Medicare Advantage and Part D premiums from being automatically deducted from the Social Security payments of some people with Medicare. Normally, if a beneficiary elects, Social Security deducts the premiums and sends them directly to the plan. In this instance, the payments were not sent to the plans, and beneficiaries did not know that their plans were not receiving them.

A new issue brief from the Kaiser Family Foundation indicates that people with Medicare who choose Medicare Advantage (MA) plans have lower Medicare spending and use fewer services relative to their peers with Original Medicare, even before they enroll in MA.

The Medicare Trustee’s report underscores what we already know: Medicare is strong and built to last. We urge lawmakers to pursue commonsense reforms—like reversing the tax bill’s troubling trajectory, reigning in high prescription drug prices, and eliminating Medicare Advantage overpayments—to ensure it stays that way.

A new report from the AARP Public Policy Institute (PPI) examines trends in prices for 390 generic prescription drugs widely used by older adults. The report found that retail prices for these drugs fell by an average of 9.3% between 2016 and 2017; the general inflation rate rose by 2.1% during the same period. This follows two consecutive years of substantial generic drug price decreases; the previous two years saw prices increase.

The President’s budget is a powerful document, as it represents the Trump administration’s vision for the country—a roadmap for where it would like lawmakers to go. It reflects the administration’s fiscal and programmatic priorities, which again this year do not include people with Medicare.

Further, because many older adults and people with disabilities look to a constellation of programs to stay healthy as they age, the budget’s Medicare cuts alone don’t tell the full story of how the administration’s vision for the future would impact beneficiaries.

In January, Congress temporarily extended two important Medicaid provisions that help older adults and people with disabilities live at home and participate in the community—the home and community-based (HCBS) spousal impoverishment protection and the Money Follows the Person (MFP) program.

Unless Congress acts soon, these programs will expire on March 31. Take action to help protect Medicaid HCBS.

A new report from the Consumer Financial Protection Bureau (CFPB)—the government agency charged with enforcing federal consumer financial laws—sheds light on the widespread problem of elder financial abuse.

Studies show that financial exploitation is the most common form of elder abuse. Perpetrators can include a wide variety of people ranging from close family members to offshore scammers, and estimates of annual losses to older adults have ranged from $2.9 billion to $36.5 billion.

When the 116th Congress convened in January, it ushered in a dramatic shift in political dynamics. For the first time in eight years, Democrats have a majority in the U.S. House of Representatives. With Republicans still in control of the U.S. Senate, the two chambers of Congress will be divided for at least the next two years.

Under split-party control, legislation will require bipartisan support in order to pass. The need for this agreement greatly, if temporarily, blunts the acute legislative threats to Medicare, Medicaid, and the Affordable Care Act (ACA) that dominated the last Congress.

With extensive program overhauls unlikely to succeed this year, we expect lawmakers to instead focus on areas of shared consensus and concern. This includes “must-pass” items, like expiring health care programs, as well as those that are a top priority for both chambers, such as high prescription drug prices.

The Medicare Rights Center recently responded to a proposed rule from the Centers for Medicare & Medicaid Services (CMS) that would, in part, allow Part D and Medicare Advantage (MA) prescription drug plans greater flexibility in managing their formularies.

According to CMS, the proposed policies are intended to “remove administrative hurdles to offer lower cost options to seniors and provide support for private sector partners by providing them the tools to lower the cost of prescription drugs.”

While we agree with the need to address high and rising drug prices, we strongly disagree with the agency’s proposed approach, which seeks to do so by weakening the protected classes protections and permitting step therapy for Part B drug coverage. Such changes have the dangerous potential to disrupt or even end access to some medications for people with Medicare.

While Medicare Part D has made prescription drugs more affordable for people with Medicare, many beneficiaries continue to face affordability challenges, in part because there is no hard cap on out-of-pocket spending under Part D. A new resource from the Kaiser Family Foundation examines the financial burden this places on Part D enrollees who rely on high-cost medications.